Keros Therapeutics (NASDAQ:KROS) Raised to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Keros Therapeutics from “strong sell” to “sell,” while the broader analyst consensus remains “Hold” with an average price target of $20.50.
• KROS shares opened at $11.03 and remain near the lower end of their 12-month range of $9.69 to $22.55. The company also missed quarterly earnings estimates, reporting a loss of $1.45 per share versus the expected $1.34 loss.
• Insiders sold 13,768 shares worth approximately $145,000 over the past 90 days, while institutional investors own 71.56% of the company.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued on Monday.

KROS has been the topic of a number of other research reports. Zacks Research lowered Keros Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 29th. Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research report on Tuesday, August 4th. Leerink Partners decreased their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research note on Tuesday, August 4th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $20.50.

Keros Therapeutics Stock Performance

Shares of KROS opened at $11.03 on Monday. The firm has a market cap of $218.72 million, a PE ratio of -2.98 and a beta of 0.99. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55. The stock has a fifty day moving average price of $10.71 and a 200-day moving average price of $11.80.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, research analysts forecast that Keros Therapeutics will post -5.16 EPS for the current year.

Insider Activity

In other news, Director Nima Farzan sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the sale, the director directly owned 9,767 shares of the company's stock, valued at $104,799.91. This represents a 21.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the firm's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 10,958 shares in the company, valued at $117,579.34. This trade represents a 19.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,768 shares of company stock worth $144,979 in the last ninety days. Corporate insiders own 12.60% of the company's stock.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KROS. The Manufacturers Life Insurance Company boosted its position in Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company's stock worth $166,000 after purchasing an additional 988 shares in the last quarter. UBS Group AG increased its position in shares of Keros Therapeutics by 1.1% in the third quarter. UBS Group AG now owns 103,864 shares of the company's stock valued at $1,643,000 after buying an additional 1,091 shares in the last quarter. Strs Ohio increased its position in shares of Keros Therapeutics by 3.9% in the fourth quarter. Strs Ohio now owns 29,300 shares of the company's stock valued at $597,000 after buying an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock valued at $33,000 after buying an additional 1,166 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after buying an additional 1,888 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source